Parmax Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 540359
₹137.75
▲ 1.35 (0.99%)
Sept. 28, 2026 · BSE · bse_bhavcopy
Quality
50/100
Moderate
Valuation
—/100
Data unavailable
Momentum
65/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹52 Cr
PE (TTM)
Data unavailable.
Price to Book
-8.4
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
233.2
Free Cash Flow
₹-3 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
388.24%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-0.73%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-17.64%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
387.58%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
323.33%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.74
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-1.87
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.32
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
26.76%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
29.55%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-8.92%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-14.15%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-84.80%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
64.58%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-1.87)
  • Yes Return on equity is 15% or more (64.6%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 4 met
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.0%
Low 136.9500 · High 137.7500
1W return
1.0%
Low 136.9500 · High 137.7500
1M return
5.0%
Low 132.4500 · High 137.7500
52W return
233.2%
Low 104.7000 · High 137.7500
Lifetime High ₹137.7500 (Sept. 28, 2026)
Lifetime Low ₹12.5000 (March 17, 2017)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
134.9
10D
128.8
20D
111.9
50D
79.1
100D
58.9
200D
39.3

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

137.48
Pivot
First resistance138.02
Second resistance138.28
Third resistance138.82
First support137.22
Second support136.68
Third support136.42
Day RSI96.1
Day MFI100.0
Day MACD22.76
Day MACD signal23.12

Beta

1M—
3M—
1Y—
3Y0.11

Price change analysis

↑ 5.0%
Over 1 Month
LowHigh
132.45137.75
↑ 233.2%
Over 3 Months
LowHigh
104.70137.75
↑ 233.2%
Over 6 Months
LowHigh
104.70137.75
↑ 233.2%
Over 1 Year
LowHigh
104.70137.75
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹8 Cr
Net profit (June 30, 2026)
₹2 Cr
Basic EPS (June 30, 2026)
₹5.8800

Ranks #150 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter30.80%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 30.80% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
24 Aug 2026 RAJESH JOSEPH Bulk Buy 20,000 131.1500 BSE
5 Aug 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 30,000 101.6500 BSE
5 Aug 2026 RAJESH JOSEPH Bulk Buy 55,751 100.6300 BSE
31 Jul 2026 PARESH DHIRAJLAL SHAH Bulk Sell 25,427 104.7800 BSE
30 Jul 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 30,000 111.0000 BSE
30 Jul 2026 PARESH DHIRAJLAL SHAH Bulk Buy 30,000 111.0000 BSE
30 Jul 2026 GUTTIKONDA VARA LAKSHMI Bulk Sell 87,547 111.0000 BSE
27 Jul 2026 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Buy 10,897 104.8800 BSE
27 Jul 2026 EPITOME TRADING AND INVESTMENTS Bulk Sell 21,312 100.7800 BSE
27 Jul 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 25,790 100.7800 BSE

All bulk and block deals →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Parmax Pharma Ltd - 540359 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Parmax Pharma Ltd - 540359 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 Insider Trading / SAST Parmax Pharma Ltd - 540359 - Closure of Trading Window
28 Sep 2026 Company Update Parmax Pharma Ltd - 540359 - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company
9 Sep 2026 Company Update Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Sep 2026 Insider Trading / SAST Parmax Pharma Ltd - 540359 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (64.6%)
  • Strong net profit margin (26.8%)
  • Strong revenue growth YoY (323.3%)

Weaknesses

  • Negative shareholder equity (Debt/Equity -1.87) -- accumulated losses exceed paid-in capital
  • Tight liquidity (Current Ratio 0.74)

Opportunities

Data unavailable.

Threats

  • RSI in overbought territory (96.1)
  • Weak interest coverage (-1.3x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Parmax Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.